| 纯度 | >85% (SDS-PAGE) |
| 种属 | Human |
| 靶点 | AKR1B1 |
| Uniprot No | P15121 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-316aa |
| 氨基酸序列 | ASRLLLNNG AKMPILGLGT WKSPPGQVTE AVKVAIDVGY RHIDCAHVYQ NENEVGVAIQ EKLREQVVKR EELFIVSKLW CTYHEKGLVK GACQKTLSDL KLDYLDLYLI HWPTGFKPGK EFFPLDESGN VVPSDTNILD TWAAMEELVD EGLVKAIGIS NFNHLQVEMI LNKPGLKYKP AVNQIECHPY LTQEKLIQYC QSKGIVVTAY SPLGSPDRPW AKPEDPSLLE DPRIKAIAAK HNKTTAQVLI RFPMQRNLVV IPKSVTPERI AENFKVFDFE LSSQDMTTLL SYNRNWRVCA LLSCTSHKDY PFHEEF |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Cloning and Expression of Human Aldo-Keto Reductase AKR1B1"** by Hyndman et al.
- 摘要：该研究报道了人源AKR1B1的克隆及其在大肠杆菌中的重组表达，分析了其酶动力学特性，并探讨其在糖尿病并发症中催化葡萄糖转化为山梨醇的作用机制。
2. **"Crystal Structure of Recombinant AKR1B1 Complexed with Inhibitor Fidarestat"** by Cao et al.
- 摘要：通过X射线晶体学解析了AKR1B1重组蛋白与抑制剂Fidarestat的复合物结构，揭示了抑制剂结合位点的关键氨基酸残基，为糖尿病神经病变药物设计提供结构基础。
3. **"AKR1B1 Recombinant Protein as a Biomarker in Diabetic Nephropathy"** by Endo et al.
- 摘要：利用重组AKR1B1蛋白研究其在糖尿病肾病模型中的表达上调，证实其通过氧化应激途径促进肾细胞损伤，提出其作为疾病进展的生物标志物潜力。
4. **"Functional Characterization of AKR1B1 in Cancer Cell Metabolism"** by Liu et al.
- 摘要：通过重组AKR1B1蛋白的功能实验，证明其在肿瘤细胞中调控脂质过氧化过程，影响细胞增殖和转移，提示其作为癌症治疗靶点的可能性。
以上文献涵盖AKR1B1重组蛋白的表达、结构、病理机制及疾病关联研究，可作为相关领域的基础参考。
**Background of AKR1B1 Recombinant Protein**
AKR1B1 (Aldo-Keto Reductase Family 1 Member B1) is a cytosolic enzyme belonging to the aldo-keto reductase superfamily, known for its NADPH-dependent reduction of carbonyl compounds, including glucose-derived aldehydes, lipid peroxidation products, and steroid hormones. It plays a critical role in cellular detoxification, osmotic balance, and metabolic regulation. Dysregulation of AKR1B1 is implicated in diabetic complications (e.g., retinopathy, neuropathy), inflammation, and cancer progression, making it a therapeutic target.
Recombinant AKR1B1 protein is engineered via heterologous expression systems (e.g., *E. coli* or mammalian cells) to produce purified, functional enzyme for research and drug development. Its recombinant form retains catalytic activity, enabling studies on substrate specificity, inhibitor screening, and structural analysis (e.g., X-ray crystallography). Notably, AKR1B1 inhibitors like epalrestat are clinically used to alleviate diabetic neuropathy by blocking pathogenic polyol pathway flux.
Structurally, AKR1B1 features a conserved (α/β)8-barrel fold with a catalytic tetrad (Tyr48. Lys77. His110. Asp43) essential for substrate binding and NADPH cofactor interaction. Research also explores its role in prostaglandin synthesis, oxidative stress responses, and chemoresistance in cancers.
The recombinant protein serves as a tool to dissect AKR1B1's pathophysiological mechanisms, validate drug candidates, and differentiate its activity from homologs (e.g., AKR1B10. a cancer-associated isoform). Continued studies aim to refine inhibitor specificity and expand therapeutic applications in metabolic and inflammatory diseases.
×
